CONTEXT: As men age, the prevalence of frailty increases whereas levels of androgens decline. Little is known about the relation between these factors. OBJECTIVE: The aim of this study was to assess cross-sectional and longitudinal associations of estradiol, bioavailable estradiol, testosterone, bioavailable testosterone (bioT), and SHBG with frailty status. DESIGN AND SETTING: The Osteoporotic Fractures in Men (MrOS) study was conducted at six U.S. clinical centers. PARTICIPANTS: A total of 1469 community-dwelling men at least 65 yr old with baseline data participated; 1245 men had frailty status reassessed 4.1 yr later. MAIN OUTCOME MEASURE: Proportional odds models estimated the likelihood of greater frailty status. Frail men had at least three of the following: weakness, slowness, low activity, exhaustion, and shrinking/sarcopenia; intermediate men had one or two criteria; and robust men had none. At follow-up, death was included as an additional ordinal outcome. Sex hormones were assayed by spectrometry/chromatographic methods. RESULTS: In cross-sectional analyses, men in the lowest quartile of bioT had 1.39-fold (95% confidence interval, 1.02, 1.91) increased odds of greater frailty status compared to men in the highest quartile after adjustment for covariates including age, body size, health status, and medical conditions. In age-adjusted longitudinal analyses, men in the lowest quartile of bioT had 1.51-fold (95% confidence interval, 1.10, 2.07) increased odds of greater frailty status 4.1 yr later. This association was largely attenuated by adjustment for covariates. No other hormones were associated in a cross-sectional or longitudinal manner with frailty status after adjustment. CONCLUSIONS: Low levels of bioT were independently associated with worse baseline frailty status. Frailty status should be considered as an outcome in trials of testosterone supplementation.
CONTEXT: As men age, the prevalence of frailty increases whereas levels of androgens decline. Little is known about the relation between these factors. OBJECTIVE: The aim of this study was to assess cross-sectional and longitudinal associations of estradiol, bioavailable estradiol, testosterone, bioavailable testosterone (bioT), and SHBG with frailty status. DESIGN AND SETTING: The Osteoporotic Fractures in Men (MrOS) study was conducted at six U.S. clinical centers. PARTICIPANTS: A total of 1469 community-dwelling men at least 65 yr old with baseline data participated; 1245 men had frailty status reassessed 4.1 yr later. MAIN OUTCOME MEASURE: Proportional odds models estimated the likelihood of greater frailty status. Frail men had at least three of the following: weakness, slowness, low activity, exhaustion, and shrinking/sarcopenia; intermediate men had one or two criteria; and robust men had none. At follow-up, death was included as an additional ordinal outcome. Sex hormones were assayed by spectrometry/chromatographic methods. RESULTS: In cross-sectional analyses, men in the lowest quartile of bioT had 1.39-fold (95% confidence interval, 1.02, 1.91) increased odds of greater frailty status compared to men in the highest quartile after adjustment for covariates including age, body size, health status, and medical conditions. In age-adjusted longitudinal analyses, men in the lowest quartile of bioT had 1.51-fold (95% confidence interval, 1.10, 2.07) increased odds of greater frailty status 4.1 yr later. This association was largely attenuated by adjustment for covariates. No other hormones were associated in a cross-sectional or longitudinal manner with frailty status after adjustment. CONCLUSIONS: Low levels of bioT were independently associated with worse baseline frailty status. Frailty status should be considered as an outcome in trials of testosterone supplementation.
Authors: L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie Journal: J Gerontol A Biol Sci Med Sci Date: 2001-03 Impact factor: 6.053
Authors: Arny A Ferrando; Melinda Sheffield-Moore; Catherine W Yeckel; Charles Gilkison; Jie Jiang; Alison Achacosa; Steven A Lieberman; Kevin Tipton; Robert R Wolfe; Randall J Urban Journal: Am J Physiol Endocrinol Metab Date: 2002-03 Impact factor: 4.310
Authors: Kristine E Ensrud; Susan K Ewing; Brent C Taylor; Howard A Fink; Peggy M Cawthon; Katie L Stone; Teresa A Hillier; Jane A Cauley; Marc C Hochberg; Nicolas Rodondi; J Kathleen Tracy; Steven R Cummings Journal: Arch Intern Med Date: 2008-02-25
Authors: Majon Muller; Diederick E Grobbee; Jos H H Thijssen; Annewieke W van den Beld; Yvonne T van der Schouw Journal: Trends Endocrinol Metab Date: 2003-08 Impact factor: 12.015
Authors: Peggy M Cawthon; Lynn M Marshall; Yvonne Michael; Thuy-Tien Dam; Kristine E Ensrud; Elizabeth Barrett-Connor; Eric S Orwoll Journal: J Am Geriatr Soc Date: 2007-08 Impact factor: 5.562
Authors: Kristine E Ensrud; Susan K Ewing; Peggy M Cawthon; Howard A Fink; Brent C Taylor; Jane A Cauley; Thuy-Tien Dam; Lynn M Marshall; Eric S Orwoll; Steven R Cummings Journal: J Am Geriatr Soc Date: 2009-02-22 Impact factor: 5.562
Authors: Ruth E Hubbard; M Sinead O'Mahony; George M Savva; Brian L Calver; Ken W Woodhouse Journal: J Cell Mol Med Date: 2009-03-06 Impact factor: 5.310
Authors: Joanne B Krasnoff; Shehzad Basaria; Michael J Pencina; Guneet K Jasuja; Ramachandran S Vasan; Jagadish Ulloor; Anqi Zhang; Andrea Coviello; Margaret Kelly-Hayes; Ralph B D'Agostino; Philip A Wolf; Shalender Bhasin; Joanne M Murabito Journal: J Clin Endocrinol Metab Date: 2010-04-09 Impact factor: 5.958
Authors: Alden L Gross; Michelle C Carlson; Nadia M Chu; Mara A McAdams-DeMarco; Dan Mungas; Eleanor M Simonsick; Ravi Varadhan; Qian-Li Xue; Jeremy Walston; Karen Bandeen-Roche Journal: Mech Ageing Dev Date: 2020-05-11 Impact factor: 5.432